Piracetam

Alzheimer Disease

Janssen-Cilag G.m.b.HSmall moleculeDormant

D

25/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 12/ 100
Competitive Position: 65/ 100

Competitive context

317 Active assets in the Alzheimer Disease cohort.

Asset / Sponsor	Phase	Rating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Akiva Mintz	Phase 4	BBB
Namenda Carnot Laboratories	Phase 4	BBB
Cipralex NYU Langone Health	Phase 4	BBB
Rivastigmine Anhui Provincial Hospital	Phase 4	BBB
Sertraline AstraZeneca	Phase 4	BBB

View all 50 →

Same molecule, other indications

Piracetam is also rated in:

middle cerebral artery infarctionDormant

CCC

Indicative ·

48 / 100

physiological malfunction arising from mental factorDormant

CC

Indicative ·

45 / 100

dementiaDormant

CC

Indicative ·

45 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.